Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice

Full text
Show less -
Freyn, Alec W. [1, 2] ; da Silva, Jamile Ramos [3, 4] ; Rosado, Victoria C. [1] ; Bliss, Carly M. [1] ; Pine, Matthew [4] ; Mui, Barbara L. [5] ; Tam, Ying K. [5] ; Madden, Thomas D. [5] ; de Souza Ferreira, Luis Carlos [3] ; Weissman, Drew [4] ; Krammer, Florian [1] ; Coughlan, Lynda [1] ; Palese, Peter [1, 6] ; Pardi, Norbert [4] ; Nachbagauer, Raffael [1]
Total Authors: 15
[1] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 - USA
[2] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 - USA
[3] Univ Sao Paulo, Biomed Sci Inst, Dept Microbiol, Vaccine Dev Lab, Sao Paulo - Brazil
[4] Univ Penn, Dept Med, Philadelphia, PA 19104 - USA
[5] Acuitas Therapeut, Vancouver, BC - Canada
[6] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 - USA
Total Affiliations: 6
Document type: Journal article
Source: MOLECULAR THERAPY; v. 28, n. 7, p. 1569-1584, JUL 8 2020.
Web of Science Citations: 1

Influenza viruses are respiratory pathogens of public health concern worldwide with up to 650,000 deaths occurring each year. Seasonal influenza virus vaccines are employed to prevent disease, but with limited effectiveness. Development of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is necessary for reducing influenza virus prevalence. In this study, we have utilized lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccines to intradermally deliver a combination of conserved influenza virus antigens (hemagglutinin stalk, neuraminidase, matrix-2 ion channel, and nucleoprotein) and induce strong immune responses with substantial breadth and potency in a murine model. The immunity conferred by nucleoside-modified mRNA-lipid nanoparticle vaccines provided protection from challenge with pandemic H1N1 virus at 500 times the median lethal dose after administration of a single immunization, and the combination vaccine protected from morbidity at a dose of 50 ng per antigen. The broad protective potential of a single dose of combination vaccine was confirmed by challenge with a panel of group 1 influenza A viruses. These findings support the advancement of nucleoside-modified mRNA-lipid nanoparticle vaccines expressing multiple conserved antigens as universal influenza virus vaccine candidates. (AU)

FAPESP's process: 19/01523-3 - mRNA-based vaccines targeting HPV-induced tumors
Grantee:Jamile Ramos da Silva
Support Opportunities: Scholarships abroad - Research Internship - Doctorate